POSEIDON trial phase 1B results : Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients
- Publication date
- 15 November 2019
- Publisher